EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

• Conditions: Advanced (localized disease but surgically unresectable or metastatic)histologically/cytologically proven hepatocellular carcinoma (or hepatic lesion and aFP ³ 400 ng/ml).; MedDRA version: 8.1Level: LLTClassification code 10007284Term: Carcinoma

• Registration Number: EUCTR2005-005732-27-DK
• Lead Sponsor: Policlinico Universitario Agustino Gemelli

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12-06
• Last Update Posted: 22 April 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
1. Advanced (localized disease but surgically unresectable or metastatic)
histologically/cytologically proven hepatocellular carcinoma (or hepatic lesion and aFP ³ 400 ng/ml).
2. No prior chemotherapy for metastatic disease.
3. No previous local treatment (RF, PEI, CE) on target lesions.
4. No previous immunotherapy.
5. Adequate bone marrow function as defined by:
?ANC =1500 cells/mm3.
??Platelets =75, 000 cells/mm3.
??Hemoglobin =9 g/dL (which may be obtained by transfusion or growth factor support.
6. Adequate liver function as defined by:
??Bilirubin =1.5 times upper limit of normal (x ULN).
??AST and ALT = 3 x ULN.
??Alkaline phosphate = 3 x ULN.
7. Adequate renal function as defined by both:
??Serum creatinine =1.5 x ULN.
8. No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart on the same day (The baseline systolic blood pressure readings must be less than or equal to 140 mm Hg, and the baseline diastolic blood pressure readings must be less than or equal to 90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible).
9. ECOG performance status of 0, 1, or 2 (See Appendix 1).
10. Life expectancy =12 weeks.
11. Adults =18 years of age.
12. Negative serum or urine pregnancy test for women of child-bearing potential.
13. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the trial patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Prior treatment with any chemotherapy agent, VEGF/VEGFR inhibitors, or anti-angiogenesis treatment.
2. Patients with locally advanced disease who are candidates for a radical surgical treatment.
3. Current use or anticipated need for drugs that are known CYP3A4 inhibitors (ie, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, ergot derivatives, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, and delavirdine) during the course of study.
4. Current use or anticipated need for drugs that are known CYP3A4 or CYP1A2 inducers (ie, carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampin, and St John’s wort) during the course of study.
5. Requirement of anticoagulant therapy except for low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis (DVT).
6. Uncontrolled brain metastases (a controlled brain metastasis must be previously treated, asymptomatic, and without growth for 4 months).
7. Inability to take oral medications.
8. History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months.
9. Major surgical procedure within 4 weeks of treatment.
10. Unstable or severe intercurrent medical condition that, in the opinion of the investigator, might interfere with achievement of study objectives.
11. Psychological or sociological conditions, addictive disorders, or family problems, whichwould preclude compliance with the protocol.
12. History of a malignancy (other than hepatocellular carcinoma) except those patients treated with curative intent for skin cancer (other than melanoma) or in situ cervical cancer or those treated with curative intent for any other cancer with no evidence of disease.
13. Patients having procreative potential who are not taking careful precautions to prevent pregnancy
14. Women who are pregnant or breast-feeding.
15. Patients with proteinuria. (Patients with >1+ protein on urine dipstick at baseline should undergo a 24-hour urine collection. Results must demonstrate =500 mg of protein in 24 hours to allow participation in the study.
16. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified